Research Areas
Oncology
Cancer remains one of the most critical threats to human health, and is a core therapeutic focus at NovaBridge. Our oncology pipeline includes Givastomig, a CLDN18.2 × 4-1BB bispecific antibody; Ragistomig, a PD-L1 × 4-1BB bispecific antibody; and Uliledlimab, an anti-CD73 monoclonal antibody.
Ophthalmology (Visara)
Ophthalmic diseases are numerous and have complex causes. In particular, retinal diseases represent a leading cause of blindness in adults worldwide. Our subsidiary, Visara, Inc. , is focused on developing innovative therapies, including our core pipeline asset VIS-101 (a VEGF-A/ANG2 bispecific antibody).
Other Areas
To address unmet clinical needs, we are actively pursuing several promising therapeutic fields, and continuously expanding our R&D pipeline to provide innovative and effective therapies for more patients.
Global Biotech Platform (NASDAQ:NBP)
Accelerating access to innovative medicines
The Hub-and-Spoke Platform Linking Global Markets
The first and only listed Hub-and-Spoke platform dedicated to bringing Asian innovative medicines to global markets
A Potential FIC and BIC Claudin 18.2 × 4-1BB Bispecific Antibody Candidate
FDA confirms Givastomig’s potential eligibility for accelerated approval pathway
A Potential BIC VEGF-A x ANG-2 Bispecific Antibody Candidate
VIS-101, a novel tetravalent bispecific antibody designed to be a potential best-in-class treatment for retinal vascular diseases